<DOC>
	<DOCNO>NCT00419809</DOCNO>
	<brief_summary>SB-681323 p38 MAP-kinase inhibitor potential us inflammatory condition RA . Previous p38 MAP-kinase inhibitor hinder development liver toxicity . Methotrexate ( common treatment RA patient ) also potential liver toxicity . This study enable study determine safety co-administration two compound respect liver function</brief_summary>
	<brief_title>SB-681323-Methotrexate Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Male female . Females must nonchildbearing capacity BMI 19 30 kg/m2 ( inclusive ) Diagnosis RA accord revised 1987 criterion American College Rheumatology ( ACR ) Negative urine drug abuse screen , breath alcohol test , hepatitis B C , HIV test . Liver function test within normal limit Must stable dose methotrexate ( 2.5 25 mg/week ) &gt; 8 week prior enrolment change course study . Must stable folate supplement &gt; 8 week prior enrolment normal red cell folate level enrollment . History alcohol &amp; /or drug abuse Abnormal ECGs screen Liver disease , uncontrolled hypertension , diabetes mellitus , psoriasis , history peptic ulcer disease The patient use glucocorticoid dos &gt; 10mg/day . The patient use sulphasalazine dose &gt; 3g/day . The patient use hydroxychloroquine dose &gt; 400mg/day . The patient treatment regimen DMARDs MTX plus one sulphasalazine hydrochloroquine ( e.g . leflunomide ) The patient dose NSAIDs , COX2 inhibitor glucocorticoid change time 2 week prior enrolment end clinical phase study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>methotrexate ,</keyword>
	<keyword>SB-681323 ,</keyword>
	<keyword>p38 MAP Kinase Inhibitor ,</keyword>
	<keyword>liver function</keyword>
	<keyword>Rheumatoid Arthritis ,</keyword>
</DOC>